Kopran
Healthcare
KOPRAN NSE
₹249.45 +3.29 (+1.34%)
- P/E
- 48.16
Close 4 Nov 2026 ₹249.45 +89.03 +55.5% 1Y
Start ₹160.42
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 6.65%
- Debt to Equity
- 0.29
- EPS (TTM)
- ₹5.18
- Book Value
- ₹109.25
- Market Cap
- —
- P/E (TTM)
- 48.16
- P/B
- 2.28
- ROE
- 4.91%
- Dividend Yield
- 1.22%
- EBITDA
- ₹62.30 Cr
- 52W High
- ₹295.83
- 52W Low
- ₹107.00
- Day Range
- ₹237.10 – ₹253.70
- Volume
- 4,14,339
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Kopran (this company) | ₹249.45 | 48.16 | ₹1,149 Cr | 2.28 | 1.22% | 4.91% | 6.65% | ₹700 Cr | ₹25 Cr |
| Median 8 companies | ₹1,587.70 | 43.49 | ₹1,25,337 Cr | 4.57 | 0.70% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
54 Average
Data confidence 100/100
Category scores
- Quality
- 56
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 59
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 43
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 39
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 82
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 51
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 40.8%
Weaknesses
3- The company has delivered a poor sales growth of 6.74% over past five years.
- Company has a low return on equity of 7.71% over last 3 years.
- Company might be capitalizing the interest cost
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Neutral | 6 | 7 | 6 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Bearish
Bearish
2
Neutral
7
Bullish
0
Overall
Neutral
Bearish
6
Neutral
7
Bullish
6
Moving Averages
Strong Bullish
Bearish
4
Neutral
0
Bullish
6
Key readings
- RSI (14)
- 46.79
- Neutral
- MACD (12,26,9)
- −3.23
- Bearish
- SMA (50)
- 251.41
- Bearish
- SMA (200)
- 184.07
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +8.69% |
|---|---|
| 5Y | +6.72% |
| 3Y | +7.32% |
| 1Y | +8.10% |
| TTM | +11.96% |
Net profit
| 10Y | +8.98% |
|---|---|
| 5Y | −15.95% |
| 3Y | −1.25% |
| 1Y | −33.33% |
| TTM | −28.42% |
Operating cash flow
| 10Y | +8.73% |
|---|---|
| 5Y | +2.23% |
| 3Y | +25.37% |
| 1Y | +59.52% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −1.04 pp |
|---|---|
| 5Y | −7.57 pp |
| 3Y | −0.34 pp |
| 1Y | −2.49 pp |
| TTM | −1.78 pp |
Revenue by year
| Mar 2017 | ₹310 Cr |
|---|---|
| Mar 2018 | ₹313 Cr |
| Mar 2019 | ₹358 Cr |
| Mar 2020 | ₹360 Cr |
| Mar 2021 | ₹492 Cr |
| Mar 2022 | ₹478 Cr |
| Mar 2023 | ₹551 Cr |
| Mar 2024 | ₹615 Cr |
| Mar 2025 | ₹630 Cr |
| Mar 2026 | ₹681 Cr |
Net profit by year
| Mar 2017 | ₹20.00 Cr |
|---|---|
| Mar 2018 | ₹20.00 Cr |
| Mar 2019 | ₹24.00 Cr |
| Mar 2020 | ₹21.00 Cr |
| Mar 2021 | ₹62.00 Cr |
| Mar 2022 | ₹61.00 Cr |
| Mar 2023 | ₹27.00 Cr |
| Mar 2024 | ₹51.00 Cr |
| Mar 2025 | ₹39.00 Cr |
| Mar 2026 | ₹26.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 153 | 159 | 186 | 139 | 152 | 166 | 172 | 135 | 118 | 194 | 234 | 154 | 211 |
| Expenses | 111 | 130 | 135 | 164 | 121 | 137 | 146 | 155 | 121 | 123 | 177 | 201 | 138 | 196 |
| Operating Profit | 6.31 | 22.83 | 23.58 | 21.69 | 18.16 | 14.73 | 19.85 | 17.09 | 14.13 | −5.28 | 17.76 | 32.94 | 15.81 | 15.41 |
| OPM % | 5.39% | 14.96% | 14.84% | 11.66% | 13.02% | 9.72% | 11.94% | 9.92% | 10.45% | −4.48% | 9.14% | 14.08% | 10.27% | 7.29% |
| Other Income | 2.39 | 0.13 | 2.43 | 9.67 | 2.63 | 1 | 0.17 | 3.26 | 2.56 | 0.03 | 0.07 | 0.09 | 2.05 | 0.62 |
| Interest | 1.83 | 1.94 | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 | 2.09 | 2.67 | 3.17 | 3.28 | 4.25 |
| Depreciation | 3.26 | 2.77 | 3.27 | 3.59 | 3.87 | 3.85 | 4 | 3.87 | 4.26 | 4.28 | 4.42 | 4.52 | 5.77 | 5.89 |
| PBT | 3.61 | 18.25 | 20.5 | 25.18 | 14.73 | 9.64 | 13.86 | 13.71 | 9.89 | −11.63 | 10.74 | 25.35 | 8.8 | 5.89 |
| Tax % | 22.99% | 24.55% | 23.02% | 26.01% | 24.69% | 23.42% | 24.96% | 29.39% | 24.67% | −14.63% | 13.04% | 25.57% | 23.84% | 25.47% |
| Net Profit | 2.77 | 13.77 | 15.79 | 18.62 | 11.1 | 7.38 | 10.4 | 9.68 | 7.45 | −9.92 | 9.34 | 18.87 | 6.7 | 4.39 |
| EPS (₹) | 0.57 | 2.86 | 3.28 | 3.86 | 2.3 | 1.53 | 2.16 | 2.01 | 1.54 | −2.06 | 1.94 | 3.91 | 1.39 | — |
Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 615 | 630 | 681 | 700 |
| Expenses | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 540 | 557 | 619 | 639 |
| Operating Profit | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 74 | 73 | 62 | 61 |
| OPM % | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 12% | 12% | 9% | 9% |
| Other Income | −48 | 1 | 11 | 9 | 3 | 0 | 18 | 11 | 3 | 15 | 4 | 0 | 2 |
| Interest | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 9 | 9 | 10 | 11 |
| Depreciation | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 13 | 16 | 17 | 19 |
| PBT | −39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 68 | 52 | 34 | 33 |
| Tax % | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | 25% | 26% | 25% | — |
| Net Profit | −39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 51 | 39 | 26 | 25 |
| EPS (₹) | −9.52 | 2.48 | 4.6 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 10.57 | 7.99 | 5.33 | 5.18 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% | 28% | 38% | 56% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 | 48 | 48 |
| Reserves | 49 | 57 | 81 | 101 | 125 | 146 | 202 | 378 | 391 | 443 | 470 | 482 |
| Borrowings | 86 | 80 | 95 | 89 | 97 | 88 | 66 | 75 | 75 | 99 | 148 | 153 |
| Other Liabilities | 99 | 84 | 78 | 82 | 85 | 92 | 128 | 110 | 135 | 153 | 178 | 225 |
| Total Liabilities | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 908 |
| Fixed Assets | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 182 | 208 | 346 |
| CWIP | 1 | 3 | 6 | 10 | 24 | 30 | 43 | 36 | 70 | 97 | 113 | 25 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 172 | 160 | 187 | 201 | 214 | 229 | 284 | 425 | 415 | 465 | 522 | 537 |
| Total Assets | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 908 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 46 | 29 | 16 | 26 | 25 | 31 | 60 | −33 | 34 | 43 | 42 | 67 |
| Investing | −10 | −9 | −18 | −11 | −25 | −13 | −25 | −84 | −13 | −44 | −56 | −65 |
| Financing | −37 | −19 | 2 | −15 | −1 | −18 | −35 | 123 | −20 | 1 | 26 | −21 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 1 | 11 | −19 |
| Free Cash Flow | 35 | 18 | 0 | 14 | −6 | 17 | 43 | −76 | −27 | −13 | −17 | 0 |
| CFO/OP | 147 | 95 | 47 | 94 | 63 | 82 | 93 | −17 | 90 | 77 | 76 | 117 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 70 | 86 | 75 | 88 | 94 | 89 | 97 | 108 | 126 | 125 | 141 |
| Inventory Days | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 | 126 | 153 | 137 |
| Days Payable | 119 | 115 | 95 | 118 | 90 | 95 | 104 | 84 | 89 | 103 | 108 | 131 |
| Cash Conversion Cycle | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 | 149 | 170 | 146 |
| Working Capital Days | 9 | 34 | 43 | 60 | 70 | 79 | 81 | 158 | 139 | 131 | 113 | 91 |
| ROCE % | 14% | 14% | 19% | 14% | 16% | 14% | 30% | 21% | 8% | 14% | 10% | 7% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kopran insights
68 extracted metrics across FY12–FY27.
Documents
- 7 Aug 2026
- 29 Jul 2025
- 11 Feb 2025
- 18 Sep 2026
- 22 Jun 2026
- 24 Mar 2026
- 24 Dec 2025
- 26 Sep 2025
- General announcements 22 Oct 2026
- General announcements 12 Oct 2026
Frequently Asked Questions about Kopran
What does Kopran Ltd do?
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
Where is Kopran Ltd (KOPRAN) listed?
Kopran Ltd trades as KOPRAN on the NSE and under code 524280 on the BSE.
Which sector does Kopran Ltd belong to?
Kopran Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Kopran Ltd?
Kopran Ltd trades at a PE ratio of 48.16 as of 4 Nov 2026, on earnings per share of ₹5.18, against a book value of ₹109.25 per share.
What is the 52-week high and low of Kopran Ltd?
Over the last 52 weeks Kopran Ltd has traded between ₹107 and ₹295.83 as of 4 Nov 2026.
Does Kopran Ltd pay dividends?
Kopran Ltd has a dividend yield of 1.22%.
What is the Return on Equity (ROE) of Kopran Ltd?
Kopran Ltd reported a return on equity of 4.91%. Its debt-to-equity ratio is 0.29.
Company Information
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
Website kopran.com
CEO Mr. Surendra Shrikrishna Somani B.Com.
Employees 1,024
Listed 9 Jun 1999
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KOPRAN.md for Kopran Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.